Sweden
Ectin Research, founded in 2013, is a Swedish biomedical startup specializing in the development of oncology therapeutics. Their pioneering solution, MFA-370, is engineered to target and eradicate cancerous tumors, particularly focusing on metastatic bladder cancer.
The company adopts the slogan "Medicine not ‘miracle’," reflecting a commitment to scientifically-backed therapy over unsubstantiated cures. MFA-370 has demonstrated promising preclinical results, successfully inducing cell death in breast, colorectal, and prostate cancer cell lines. The therapeutic promises a straightforward treatment regimen by being an oral tablet, anticipated to have minimal side effects due to its composition of two already well-established pharmaceuticals.
The last notable investment in Ectin Research was a €50.00K grant from the European Commission back in February 2017. As clinical trials approach, potential investors have the opportunity to back a unique cancer therapy with both promising preclinical outcomes and a streamlined path through regulatory channels.
